| Autor: |
M, Kimura, E, Usami, H, Teramachi, T, Yoshimura |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Die Pharmazie. 76(7) |
| ISSN: |
0031-7144 |
| Popis: |
This study aimed to identify the overall survival prolongation index in patients who received paclitaxel plus ramucirumab as second line chemotherapy for human epidermal growth factor receptor (HER) 2-negative advanced/ recurrent gastric cancer (AGC). We included 77 patients who underwent second line chemotherapy (paclitaxel plus ramucirumab) for AGC at our institution between January 2015 and September 2020. To determine factors associated with survival, univariate and multivariate analyses were performed, and hazard ratios and their 95% confidence intervals (95% CI) were calculated. In the multivariate analysis, grade ≥1 neutropenia (yes) and the number of anti-cancer drugs used (≥5) were independently and significantly associated with survival. Compared to the patients without grade ≥1 neutropenia, patients with grade ≥1 neutropenia had a survival hazard ratio of 0.455 (95% CI: 0.214-0.966 |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
